News

GlaxoSmithKline (GSK) and Pfizer are spinning out all HIV/AIDS-related R&D and marketed drugs into a separate, jointly-controlled company.

Can anybody spare a dime for science? With the usual funding avenues blocked development-stage companies are turning to research charities.

The European Commission is to boost funding for high-risk futuristic research in ICT, to provide foundations for economic recovery and future competitiveness.